Literature DB >> 19235444

Progressive supranuclear palsy: a review of co-existing neurodegeneration.

J Keith-Rokosh1, L C Ang.   

Abstract

OBJECTIVES: The neuropathological findings of 32 progressive supranuclear palsy (PSP) cases over a period of 17 years were reviewed.
RESULTS: Of the 26 cases with adequate clinical data, 20 patients either presented with cognitive dysfunction or developed a cognitive impairment subsequently during the course of the disease. Co-existing changes of argyrophilic grains and corticobasal degeneration (CBD) were found in 28% and 32% of the cases respectively. Alzheimer-related pathology was found in 69% of cases but only 18.75% of cases fulfilled the consortium to establish a registry for Alzheimer's disease (CERAD) criteria for either definite or probable Alzheimer's disease. Lewy bodies were noted in four cases (12.5%), all in the subcortical regions. Only seven cases of PSP showed no pathological evidence of other co-existing neurodegenerative diseases. The severity of the cerebrovascular pathology in this cohort was insufficient to explain any clinical symptomatology.
CONCLUSIONS: As in previous studies, this study has demonstrated the frequent co-existence of pathological changes usually noted in other neurodegenerative diseases in PSP. Whether these co-existing pathological changes contribute to the cognitive impairment in PSP remains uncertain.

Entities:  

Mesh:

Year:  2008        PMID: 19235444     DOI: 10.1017/s0317167100009392

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  7 in total

1.  Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP?

Authors:  Virgilio Gerald H Evidente; Charles H Adler; Marwan N Sabbagh; Donald J Connor; Joseph G Hentz; John N Caviness; Lucia I Sue; Thomas G Beach
Journal:  Parkinsonism Relat Disord       Date:  2011-03-21       Impact factor: 4.891

Review 2.  Extrapyramidal syndromes in frontotemporal degeneration.

Authors:  Andrew Kertesz; Paul McMonagle; Sarah Jesso
Journal:  J Mol Neurosci       Date:  2011-09-02       Impact factor: 3.444

3.  Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Giulia Di Lazzaro; Simona Scalise; Vito Luigi Colona; Paola Imbriani; Nicola Biagio Mercuri; Sergio Bernardini; Anthony E Lang; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2018-06-14       Impact factor: 3.575

4.  Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy.

Authors:  María Elena Erro Aguirre; María Victoria Zelaya; Javier Sánchez Ruiz de Gordoa; María Teresa Tuñón; José Luis Lanciego
Journal:  Front Neuroanat       Date:  2015-03-11       Impact factor: 3.856

5.  Characterization of tau oligomeric seeds in progressive supranuclear palsy.

Authors:  Julia E Gerson; Urmi Sengupta; Cristian A Lasagna-Reeves; Marcos J Guerrero-Muñoz; Juan Troncoso; Rakez Kayed
Journal:  Acta Neuropathol Commun       Date:  2014-06-14       Impact factor: 7.801

6.  Disease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study.

Authors:  Karsten Mueller; Robert Jech; Cecilia Bonnet; Jaroslav Tintěra; Jaromir Hanuška; Harald E Möller; Klaus Fassbender; Albert Ludolph; Jan Kassubek; Markus Otto; Evžen Růžička; Matthias L Schroeter
Journal:  Front Neurosci       Date:  2017-03-07       Impact factor: 4.677

7.  How to demix Alzheimer-type and PSP-type tau lesions out of their mixture -hybrid approach to dissect comorbidity.

Authors:  Momoko Ebashi; Yoshinori Ito; Miho Uematsu; Ayako Nakamura; Katsuiku Hirokawa; Satoshi Kamei; Toshiki Uchihara
Journal:  Acta Neuropathol Commun       Date:  2019-05-06       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.